Dyne Therapeutics (NASDAQ:DYN) announced the appointment of Vikram Karnani to its Board of Directors on December 23, 2025.
The move signals a strategic shift for the clinical-stage biotech as it transitions from a research-heavy platform company to a commercial-ready entity, with its first product launch targeted for the first quarter of 2027.
Karnani currently serves as the CEO of Collegium Pharmaceutical and brings a high-profile track record in rare disease commercialization.
Most notably, he led the global commercial and medical affairs integration following Amgen’s $28 billion acquisition of Horizon Therapeutics.
During his nearly decade-long tenure at Horizon, Karnani was instrumental in scaling its rare disease revenue from $500 million to more than $3 billion, a feat Dyne hopes to replicate as it advances its proprietary FORCE™ platform.